{"blog": [], "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "1", "is_major": "N"}, {"value": "Mergers, Acquisitions and Divestitures", "name": "subject", "rank": "2", "is_major": "N"}, {"value": "Alexion Pharmaceuticals Inc", "name": "organizations", "rank": "3", "is_major": "N"}, {"value": "Food and Drug Administration", "name": "organizations", "rank": "4", "is_major": "N"}], "web_url": "http://www.nytimes.com/2015/05/07/business/dealbook/alexion-puts-its-soaring-stock-price-to-good-use.html", "document_type": "article", "byline": {"person": [{"lastname": "CYRAN", "firstname": "Robert", "role": "reported", "organization": "", "rank": 1}], "original": "By ROBERT CYRAN"}, "type_of_material": "News", "multimedia": [], "section_name": "Business Day", "word_count": "384", "source": "The New York Times", "subsection_name": "DealBook", "lead_paragraph": "The drug maker\u2019s offer for Synageva has a huge 136 percent premium. Still, exchanging a chunk of high-priced paper for assets may be a savvy move.", "pub_date": "2015-05-07T00:00:00Z", "news_desk": "Business", "headline": {"kicker": "Breakingviews", "main": "Alexion Puts Its Soaring Stock Price to Good Use", "content_kicker": "Breakingviews"}, "print_page": null, "snippet": "The drug maker\u2019s offer for Synageva has a huge 136 percent premium. Still, exchanging a chunk of high-priced paper for assets may be a savvy move.", "_id": "554ab8da38f0d85a643468ce", "slideshow_credits": null, "abstract": null}